Jakafi

(Ruxolitinib)

ApprovedSmall molecule

Ruxolitinib is used to treat certain blood disorders like myelofibrosis and polycythemia vera, as well as severe eczema. It works by reducing inflammation and helping the body's immune system function more normally.[2] Jakafi is currently approved and in use across 97 indications[4].[1]

Jakafi is one of 1494 small molecule programs targeting Polycythemia Vera. It is currently in Approved.

Indications

317

Total Trials

Active Trials

1,493

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Polycythemia VeraActive, not recruiting

Pancreatic NeoplasmApproved

CachexiaActive, not recruiting

HIV InfectionApproved

Bronchiolitis ObliteransActive, not recruiting

Breast DiseaseActive, not recruiting

Aplastic AnemiaActive, not recruiting

Malignant Atrophic PapulosisApproved

Idiopathic Multicentric Castleman DiseaseActive, not recruiting

Atopic EczemaApproved

Polycythemia VeraPhase 3

Active, not recruiting

Pancreatic NeoplasmApproved

Approved

CachexiaPhase 2

Active, not recruiting

HIV InfectionApproved

Approved

Bronchiolitis ObliteransPhase 2

Active, not recruiting

Breast DiseasePhase 2

Active, not recruiting

Aplastic AnemiaPhase 2

Active, not recruiting

Malignant Atrophic PapulosisApproved

Approved

Idiopathic Multicentric Castleman DiseasePhase 2

Active, not recruiting

Atopic EczemaApproved

Approved

Showing 10 of 97 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

5 2

Adenocard

Astellas

Preclinical

1 3

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Acupan

YYonsei University

Preclinical

1 7

Avastin

Roche

Preclinical

4 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Leukemia

NCT05592015

Phase 1/2Active, not recruiting

Histiocytosis

NCT04551131

Phase 2Active, not recruiting

Graft Versus Host Disease

NCT05622318

Phase 2Not yet recruiting

Agvhd

NCT06075225

Q4 2026

Phase 2Recruiting

Lymphoma

NCT02974647

Phase 2Recruiting

Blast Phase Myeloproliferative Neoplasm

NCT04282187

Clinical

Trials by Indication[1]

Myelofibrosis39 trials

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Completed· Incyte logo

Incyte·Phase 2·NCT03144687·23 enrolled

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01712308·56 enrolled

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Recruiting·KKartos Therapeutics, Inc.·Phase 3·NCT06479135·600 enrolled

Show 36 more trials

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Completed·JJohn Mascarenhas·Phase 2·NCT04281498·6 enrolled

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT04472598·252 enrolled

Actuate 1901: 9-ING-41 in Myelofibrosis

Completed·AActuate Therapeutics Inc.·Phase 2·NCT04218071·17 enrolled

Ruxolitinib in Patients With Myelofibrosis

Unknown status·—··NCT05762874·51 enrolled

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Terminated· Novartis logo

Novartis·Phase 2·NCT02091752·3 enrolled

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Not yet recruiting· Novartis logo

Novartis·Phase 1·NCT07340138·6 enrolled

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

Completed· Novartis logo

Novartis·Phase 1·NCT02370706·15 enrolled

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

Completed·JJohn Mascarenhas·Phase 1/2·NCT01693601·15 enrolled

Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy

Unknown status·MMargherita Maffioli··NCT03959371·620 enrolled

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Completed· Incyte logo

Incyte·Phase 2·NCT01340651·41 enrolled

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Completed· Incyte logo

Incyte·Phase 3·NCT00952289·309 enrolled

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Active, not recruiting· AbbVie logo

AbbVie·Phase 3·NCT04468984·330 enrolled

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT04603495·430 enrolled

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT02251821·61 enrolled

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Recruiting·GGeron Corporation·Phase 1·NCT05371964·36 enrolled

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05714072·18 enrolled

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Terminated· AbbVie logo

AbbVie·Phase 1·NCT04480086·1 enrolled

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Terminated· Novartis logo

Novartis·Phase 1/2·NCT04097821·45 enrolled

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Completed·—·Phase 3·NCT01969838·432 enrolled

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Recruiting· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT04176198·240 enrolled

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Completed· Novartis logo

Novartis·Phase 2·NCT02966353·51 enrolled

A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT06619522

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Completed· Incyte logo

Incyte·Phase 2·NCT01445769·45 enrolled

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Completed· Roche logo

Roche·Phase 2·NCT01981850·125 enrolled

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02267278·25 enrolled

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Terminated· Incyte logo

Incyte·Phase 2·NCT02718300·74 enrolled

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04384692·53 enrolled

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Completed· AbbVie logo

AbbVie·Phase 2·NCT03222609·191 enrolled

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Completed· Novartis logo

Novartis·Phase 3·NCT00934544·219 enrolled

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06345495·30 enrolled

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Completed·—·Phase 1·NCT02917096·18 enrolled

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Terminated· Incyte logo

Incyte·Phase 3·NCT04551066·252 enrolled

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT06773195·37 enrolled

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Active, not recruiting·KKaryopharm Therapeutics Inc·Phase 3·NCT04562389·353 enrolled

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Terminated· Incyte logo

Incyte·Phase 3·NCT04551053·177 enrolled

Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis

Completed·QQilu Hospital of Shandong University··NCT05410470·130 enrolled

Essential Thrombocythemia10 trials

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Active, not recruiting·RRWTH Aachen University·Phase 2·NCT02577926·207 enrolled

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Terminated· Incyte logo

Incyte·Phase 2·NCT00726232·73 enrolled

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Unknown status·KKartos Therapeutics, Inc.·Phase 1/2·NCT04485260·36 enrolled

Show 7 more trials

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Completed· Novartis logo

Novartis·Phase 3·NCT02087059·51 enrolled

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Terminated· Incyte logo

Incyte·Phase 2·NCT03123588·12 enrolled

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Completed· Gilead logo

Gilead·Phase 2·NCT01369498·54 enrolled

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

Terminated· Gilead logo

Gilead·Phase 1·NCT02436135·10 enrolled

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Completed· Incyte logo

Incyte·Phase 1·NCT01317875·69 enrolled

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Completed· Incyte logo

Incyte·Phase 1/2·NCT00509899·154 enrolled

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Completed· Novartis logo

Novartis·Phase 1·NCT01433445·61 enrolled

Atopic Dermatitis8 trials

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Completed· Incyte logo

Incyte·Phase 3·NCT04921969·330 enrolled

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Recruiting· Incyte logo

Incyte·Phase 3·NCT06832618·240 enrolled

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07352566·10 enrolled

Show 5 more trials

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

Completed· Incyte logo

Incyte·Phase 1·NCT05034822·29 enrolled

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Completed· Incyte logo

Incyte·Phase 3·NCT03745638·631 enrolled

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Completed· Incyte logo

Incyte·Phase 1·NCT03920852·41 enrolled

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Recruiting· Incyte logo

Incyte··NCT06259669·958 enrolled

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

Terminated· Incyte logo

Incyte·Phase 4·NCT05696392·47 enrolled

COVID-197 trials

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

No longer available· Incyte logo

Incyte··NCT04355793

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

Completed·PPrisma Health-Upstate·Phase 2·NCT04374149·20 enrolled

Ruxolitinib to Combat COVID-19

Withdrawn·WWashington University School of Medicine·Phase 2·NCT04354714

Show 4 more trials

Inflammatory Signal Inhibitors for COVID-19 (MATIS)

Completed·IImperial College London·Phase 1/2·NCT04581954·185 enrolled

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

Terminated· Incyte logo

Incyte·Phase 3·NCT04377620·211 enrolled

Safety and Efficacy of Ruxolitinib for COVID-19

Withdrawn·UUniversity of Colorado, Denver·Phase 2/3·NCT04348071

Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation

Completed·UUniversity of Jena·Phase 2·NCT04338958·193 enrolled

Polycythemia Vera7 trials

Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice

Unknown status·MMultinational Center for Quality of Life Research, Russia··NCT05566535·32 enrolled

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Completed· Novartis logo

Novartis·Phase 3·NCT02292446·161 enrolled

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

No longer available· Novartis logo

Novartis··NCT05269771

Show 4 more trials

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02493530·60 enrolled

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

Completed· Novartis logo

Novartis·Phase 3·NCT02038036·149 enrolled

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Recruiting·MMassachusetts General Hospital·Phase 2·NCT04644211·60 enrolled

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Recruiting·UUniversity of Birmingham·Phase 3·NCT04116502·586 enrolled

89 more indications

Lymphoma7 trials

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

Completed·SSamsung Medical Center·Phase 2·NCT01965119·20 enrolled

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT01877005·33 enrolled

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05010005·70 enrolled

Show 4 more trials

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT02613598·15 enrolled

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT02164500·12 enrolled

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Recruiting·JJonathan Brammer·Phase 2·NCT07356245·44 enrolled

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02974647·83 enrolled

Breast Cancer4 trials

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Active, not recruiting·—·Phase 2·NCT02876302·23 enrolled

Ruxolitinib in Patients With Breast Cancer

Terminated·—·Phase 2·NCT01562873·21 enrolled

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Completed·—·Phase 1/2·NCT02066532·32 enrolled

Show 1 more trial

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Terminated· Incyte logo

Incyte·Phase 2·NCT02120417·149 enrolled

Pancreatic Cancer3 trials

Study of Ruxolitinib in Pancreatic Cancer Patients

Completed· Incyte logo

Incyte·Phase 2·NCT01423604·136 enrolled

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Terminated· Incyte logo

Incyte·Phase 3·NCT02117479·321 enrolled

A Study of Ruxolitinib in Pancreatic Cancer Patients

Terminated· Incyte logo

Incyte·Phase 3·NCT02119663·86 enrolled

First Line Therapy3 trials

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06660355·120 enrolled

First Line Therapy for High Risk Acute GVHD

Completed·—·Phase 2·NCT04061876·198 enrolled

Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

Terminated·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT03701698·1 enrolled

Histiocytosis3 trials

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

Unknown status·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 4·NCT05491304·400 enrolled

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Recruiting·—·Phase 2·NCT06160791·36 enrolled

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT04551131·10 enrolled

Chronic Graft Versus Host Disease3 trials

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

Completed·—·Phase 1·NCT05121142·13 enrolled

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Recruiting· Incyte logo

Incyte·Phase 2·NCT06388564·120 enrolled

Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

Completed·UUniversity of Nebraska·Phase 2·NCT03616184·49 enrolled

Treatment3 trials

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Active, not recruiting· Incyte logo

Incyte·Phase 2·NCT02955940·10 enrolled

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Completed·JJohn Mascarenhas·Phase 1/2·NCT02076191·49 enrolled

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients

Completed· Novartis logo

Novartis·Phase 1·NCT02253277·5 enrolled

Acute Lymphoblastic Leukemia3 trials

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Terminated·SSt. Jude Children's Research Hospital·Phase 1·NCT03515200·12 enrolled

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT01620216·12 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

Acute Graft Versus Host Disease3 trials

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05599256·40 enrolled

Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05600855·115 enrolled

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04744116·24 enrolled

Chronic Lymphocytic Leukemia2 trials

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Unknown status·SSunnybrook Health Sciences Centre·Phase 1/2·NCT02912754·36 enrolled

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

Completed·SSunnybrook Health Sciences Centre·Phase 1/2·NCT02015208·13 enrolled

Myeloproliferative Neoplasms2 trials

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Completed·OOhio State University Comprehensive Cancer Center·Phase 1/2·NCT03878199·12 enrolled

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Recruiting· Incyte logo

Incyte·Phase 1·NCT05936359·225 enrolled

Leukemia2 trials

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT01914484·4 enrolled

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Recruiting·JJonathan Brammer·Phase 2·NCT05592015·30 enrolled

Acute Graft Vs. Host Disease2 trials

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Completed· Novartis logo

Novartis·Phase 1/2·NCT03491215·45 enrolled

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Recruiting· Novartis logo

Novartis·Phase 4·NCT06462469·36 enrolled

Hematological Malignancies2 trials

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Withdrawn·NNYU Langone Health·Phase 2·NCT04016116

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT05579769·3 enrolled

Hematopoietic Stem Cell Transplant2 trials

Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

Active, not recruiting·—·Phase 2·NCT04908735·7 enrolled

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Approved for marketing· Incyte logo

Incyte··NCT03147742

Hemophagocytic Syndrome2 trials

JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06244862·42 enrolled

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02400463·6 enrolled

aGVHD2 trials

MAGIC Ruxolitinib for aGVHD

Recruiting·JJohn Levine·Phase 2·NCT06936566·98 enrolled

MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

Not yet recruiting·SSichuan University·Phase 2·NCT06075225·62 enrolled

Advanced Malignancies2 trials

Study of INCB053914 in Subjects With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02587598·97 enrolled

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02711137·137 enrolled

Graft Vs Host Disease2 trials

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Completed·YYi-Lun Wang·Phase 3·NCT05663827·6 enrolled

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

Terminated·XXenikos·Phase 3·NCT04934670·12 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

Not yet recruiting·PPeking University People's Hospital·Phase 4·NCT06364319·118 enrolled

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT06573593·150 enrolled

Glioblastoma2 trials

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Active, not recruiting·—·Phase 1·NCT03514069·60 enrolled

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Recruiting·BBaptist Health South Florida·Phase 2·NCT06991101·190 enrolled

Bronchiolitis Obliterans2 trials

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT03674047·50 enrolled

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT05413356·50 enrolled

Thrombocytopenia2 trials

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting·KKaryopharm Therapeutics Inc·Phase 2·NCT05980806·58 enrolled

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Terminated·WWashington University School of Medicine·Phase 2·NCT04543279·3 enrolled

Myelodysplastic Syndrome2 trials

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01895842·31 enrolled

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07228624·50 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Recruiting·HHannah Choe, MD·Phase 2·NCT07249346·124 enrolled

Chuvash polycythemia1 trial

Ruxolitinib for Chuvash Polycythemia

No longer available·WWashington University School of Medicine··NCT01730755

Aplastic Anemia1 trial

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06752694·20 enrolled

Colorectal Cancer1 trial

Study of Ruxolitinib in Colorectal Cancer Patients

Terminated· Incyte logo

Incyte·Phase 2·NCT02119676·396 enrolled

Head and Neck Cancer1 trial

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

Withdrawn·UUniversity of Pittsburgh·Phase 1·NCT02593929

Prostate Cancer1 trial

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT06616155·39 enrolled

Conditioning1 trial

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT06477549·220 enrolled

Acute Myeloid Leukemia1 trial

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Recruiting·MMayo Clinic·Phase 1·NCT03017820·127 enrolled

Small Cell Lung Cancer1 trial

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Terminated· Incyte logo

Incyte·Phase 2·NCT02119650·76 enrolled

Fecal Microbiota Transplantation1 trial

Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Terminated·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT04269850·2 enrolled

Aged1 trial

Managed Access Programs for INC424, Ruxolitinib

Available· Novartis logo

Novartis··NCT04745637

Vitiligo1 trial

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Completed· Incyte logo

Incyte·Phase 3·NCT04530344·458 enrolled

Hypereosinophilic syndrome1 trial

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Recruiting·WWilliam Shomali·Phase 2·NCT03801434·10 enrolled

Inclusion Body Myositis1 trial

Ruxolitinib Treatment in Inclusion Body Myositis

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06536166·80 enrolled

ETP-ALL1 trial

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Unknown status·SSichuan University·Phase 1/2·NCT03613428·12 enrolled

Refractory1 trial

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Recruiting·—·Phase 1·NCT06233110·30 enrolled

Graft Versus Host Disease1 trial

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Active, not recruiting·MMedical College of Wisconsin·Phase 2·NCT05622318·56 enrolled

Safety and Efficacy1 trial

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT01776723·50 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03041636·1 enrolled

Myeloid Neoplasm1 trial

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Active, not recruiting· Incyte logo

Incyte·Phase 1·NCT04279847·140 enrolled

AML/MDS1 trial

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04055844·14 enrolled

Patients With Advanced Solid Tumors1 trial

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

Terminated· Incyte logo

Incyte·Phase 1·NCT01822756·42 enrolled

Lung Adenocarcinoma1 trial

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02155465·22 enrolled

Idiopathic Multicentric Castleman Disease1 trial

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT07085039·14 enrolled

Acute Promyelocytic Leukemia1 trial

Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT04446806·100 enrolled

Myeloproliferative Neoplasm1 trial

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT04041050·85 enrolled

Alopecia Areata1 trial

Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Completed·—·Phase 2·NCT01950780·12 enrolled

Allogeneic Stem Cell Transplantation1 trial

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT03286530·64 enrolled

Metastatic Prostate Cancer1 trial

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Terminated· Incyte logo

Incyte·Phase 2·NCT00638378·22 enrolled

Necrobiosis Lipoidica1 trial

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

Completed·—·Phase 2·NCT04492618·12 enrolled

Pancreatic Adenocarcinoma1 trial

Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

Unknown status·NNational Cancer Centre, Singapore·Phase 1·NCT04303403·48 enrolled

Bone Marrow Transplantation1 trial

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Completed· Incyte logo

Incyte·Phase 3·NCT03112603·330 enrolled

Sickle Cell Disease1 trial

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Not yet recruiting·UUniversity of Colorado, Denver·Phase 1/2·NCT07252050·24 enrolled

Solid Malignancies1 trial

Retifanlimab and Ruxolitinib In Solid Malignancies

Recruiting·UUniversity of California, San Diego·Phase 1/2·NCT07219576·40 enrolled

Tacrolimus1 trial

PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT

Completed·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT04669210·128 enrolled

Chronic1 trial

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT02973711

Overlap Syndrome1 trial

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

Recruiting·MMichael Savona·Phase 1/2·NCT04061421·94 enrolled

Hematopoietic Cell Transplantation1 trial

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Recruiting·WWashington University School of Medicine·Phase 1·NCT06008808·41 enrolled

Methylprednisolone1 trial

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Recruiting·OOncotherapeutics·Phase 1·NCT06225310·30 enrolled

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Completed· Incyte logo

Incyte·Phase 2·NCT02953678·71 enrolled

Acute Leukemia1 trial

Phase l/II Study of Ruxolitinib for Acute Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01251965·27 enrolled

Myeloid Leukemia1 trial

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01751425·8 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

Terminated·—·Phase 2·NCT04807777·3 enrolled

T-Cell Prolymphocytic Leukemia1 trial

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT07311746·36 enrolled

Chronic Myelomonocytic Leukemia1 trial

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT07128381·66 enrolled

Discoid Lupus Erythematosus1 trial

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Completed·UUniversity of Rochester·Phase 2·NCT04908280·10 enrolled

Relapsed or Refractory1 trial

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Unknown status·SSamsung Medical Center·Phase 2·NCT02638428·90 enrolled

Advanced Hematologic Malignancies1 trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Recruiting·SStanford University·Phase 1·NCT05088356·60 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Completed·PPeter Hosein, MD·Phase 1·NCT05440942·28 enrolled

Triple Negative1 trial

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Completed·—·Phase 1/2·NCT02041429·20 enrolled

Dexamethasone1 trial

Ruxolitinib Combined With Dexamethasone for HLH

Unknown status·—·Phase 1/2·NCT03795909·50 enrolled

Blast Phase Myeloproliferative Neoplasm1 trial

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Recruiting·UUniversity of Washington·Phase 2·NCT04282187·25 enrolled

Cachexia1 trial

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Terminated·KKantonsspital Aarau·Phase 2·NCT02072057·8 enrolled

Pneumonia1 trial

Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia

Terminated·UUniversity Health Network, Toronto·N/A·NCT04331665·3 enrolled

cGVHD1 trial

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Approved for marketing· Incyte logo

Incyte··NCT05722912

Multiple Myeloma1 trial

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Completed·WWake Forest University Health Sciences·Phase 1/2·NCT03773107·12 enrolled

Malignancies1 trial

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Completed·CConstellation Pharmaceuticals·Phase 1/2·NCT02158858·336 enrolled

Toxicities1 trial

Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

Recruiting·UUniversity of Zurich·Phase 2·NCT06399029·20 enrolled

High Risk1 trial

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Terminated·FFrench Innovative Leukemia Organisation·Phase 2/3·NCT02962388·13 enrolled

Relapsed/Refractory AML1 trial

CART123 + Ruxolitinib in Relapsed/Refractory AML

Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT06768476·12 enrolled

Hidradenitis Suppurativa1 trial

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Recruiting· Incyte logo

Incyte·Phase 3·NCT06959225·550 enrolled

Chronic Hand Eczema1 trial

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

Withdrawn· Incyte logo

Incyte·Phase 3·NCT05233410

TNBC1 trial

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Recruiting·—·Phase 1·NCT06008275·20 enrolled

Unspecified3 trials

JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT05998395·1 enrolled

ECP Combination Study

Completed·EEuropean Society for Blood and Marrow Transplantation··NCT05052385·319 enrolled

Amping up With PemJAK

Recruiting·—·Phase 2·NCT07283822·53 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 16, 2011

JAKAFI

NDA NDA202192

Sep 21, 2021

OPZELURA

NDA NDA215309

May 1, 2026

JAKAFI XR

NDA NDA217180

Sources

References

[1]
ClinicalTrials.gov — 317 trial records for Ruxolitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Jakafi drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ruxolitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ruxolitinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217180). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Jakafi. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tyrosine-Protein Kinase JAK1 Inhibitor; Tyrosine-Protein Kinase TYK2 Inhibitor; Tyrosine-Protein Kinase JAK2 Inhibitor; Tyrosine-Protein Kinase JAK3 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Incyte

Patent Landscape[6]

Patent Cliff

Dec 12, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10639310Dec 12, 2026

9974790Dec 12, 2026

9079912Dec 12, 2026

9814722Dec 12, 2026

8530485Dec 12, 2026

43 more patents

9206187Dec 12, 2026

11744832Dec 12, 2026

9814722*PEDJun 12, 2027

9974790*PEDJun 12, 2027

9079912*PEDJun 12, 2027

10639310*PEDJun 12, 2027

8415362Dec 24, 2027

7598257Dec 24, 2027

8829013Jun 12, 2028

10610530Jun 12, 2028

11213528Jun 12, 2028

8822481Jun 12, 2028

10016429Jun 12, 2028

8722693Jun 12, 2028

8415362*PEDJun 24, 2028

7598257*PEDJun 24, 2028

8822481*PEDDec 12, 2028

8829013*PEDDec 12, 2028

8722693*PEDDec 12, 2028

10610530*PEDDec 12, 2028

10016429*PEDDec 12, 2028

10758543May 20, 2031

11571425May 20, 2031

12564593May 20, 2031

12544381May 20, 2031

11590136May 20, 2031

11219624May 20, 2031

10869870May 20, 2031

12226419May 20, 2031

11219624*PEDNov 20, 2031

10758543*PEDNov 20, 2031

10869870*PEDNov 20, 2031

11576865Nov 14, 2033

10874616Nov 14, 2033

11576864Nov 14, 2033

11896717Nov 14, 2033

11337927Jan 17, 2034

11590138Jun 10, 2040

12233067Jul 28, 2040

12589096Sep 4, 2040

11510923Sep 4, 2040

11590137Sep 4, 2040

11602536May 5, 2041